Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary

Inclusion criteria

• Age 18-80
• KPS ≥ 60
• At least one recurrent or progressive brain metastasis (es) from any solid primary tumor that is visible on MRI as assessed by the patient's treating physician.
• Recurrence may occur after any treatment: recurrence after whole-brain radiation, stereotactic radiosurgery, surgical resection, systemic chemotherapy are all acceptable.
• There is no limit on the number of brain metastases.
• Surgical resection or SRS to other recurrent lesions in the same patient are acceptable, provided one recurrent lesion remains untreated.
• Systemic disease must be well-controlled or NED in the opinion of the patient's primary oncologist.

Exclusion criteria

• Inability to get brain MRI +/- contrast
• Progressive systemic disease
• Known leptomeningeal metastases
• Primary Brain tumor
• Active Intracranial Hemorrhage
• Surgery less than two weeks before enrollment
• GI hemorrhage (active or in recent 6 months)
• Concurrent anti-platelet therapy
• Concurrent anti-coagulation therapy
• Active bleeding diathesis
• Platelet count ≤ 70,000/mm3
• International normalized ratio (INR) > 1.6 and a Partial Thromboplastin Time (PTT) > 40 seconds
• Serum Creatinine >2 mg/dL OR CrCL <30ml/min
• AST or ALT > 200 U/L
• Hemoglobin <8 g/dL
• Allergy to meclofenamate or other NSAID
• Inability to tolerate PO dosing
• Steroid dose increased in the most recent two weeks.
• Pregnancy
• Cardiac Arrhythmia requiring medical management and/or pacemaker.
• Known congestive heart failure requiring medical management